We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Noninvasive Prenatal Technique Detects Subchromosomal Abnormalities

By LabMedica International staff writers
Posted on 24 Nov 2015
Print article
Image: Detection of chromosomal deletion by NIPT using maternal blood plasma (top) is similar to detection with the traditional method using fetal tissue (bottom) (Photo courtesy of UC San Diego Health).
Image: Detection of chromosomal deletion by NIPT using maternal blood plasma (top) is similar to detection with the traditional method using fetal tissue (bottom) (Photo courtesy of UC San Diego Health).
Image: The Ion Proton Sequencer System (Photo courtesy of Life Technologies).
Image: The Ion Proton Sequencer System (Photo courtesy of Life Technologies).
Noninvasive prenatal testing (NIPT) using sequencing of fetal cell-free DNA from maternal plasma has allowed accurate prenatal diagnosis of aneuploidy without requirement of an invasive procedure and this approach has gained increasing clinical acceptance.

A novel technique has been developed that uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

An international team of scientists including those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed blood plasma from 1,476 pregnant women with fetal structural abnormalities detected by ultrasound. These women also underwent an invasive diagnostic procedure and conventional fetal DNA analysis. The scientists compared that information to semiconductor sequencing results on circulating fetal DNA obtained from a blood test on the pregnant women at an average gestational age of 24 weeks.

After DNA extraction, a comparative genomic hybridization analysis (aCGH) was performed using Agilent commercial arrays (Agilent Technologies; Santa Clara, CA, USA). To obtain complete sequences of cell-free DNA (cfDNA) fragments, sequencing was performed using an Ion Proton Sequencer (Life Technologies; Carlsbad, CA, USA). The new semiconductor sequencing method detected 69 of 73 (94.5%) abnormalities of a certain size (greater than one million base pairs) detected by the conventional method. According to the investigators, the cost of NIPT with semiconductor sequencing has the potential to be less expensive than the conventional, invasive prenatal testing method, especially as genetic sequencing technologies continue to decrease in cost.

In the study, semiconductor sequencing detected 55 false positives, of which 35 (63.6%) were due to maternal, rather than fetal, chromosomal abnormalities. That means the new method will require a validation test to screen out maternal abnormalities. NIPT with semiconductor sequencing also needs to be tested at early time points in the pregnancy, at 12 to 16 weeks, and it is hoped to further improve the technique to be able to detect even smaller genetic abnormalities.

The authors concluded that methods they developed can be applied to any mixed biological sample to determine the subchromosomal abnormalities in the minor component, even when this fraction represents only a small percentage of the total DNA. In prenatal diagnostics, samples obtained from chorionic villi could be analyzed for mosaic karyotypes or maternal contamination. The study was published on November 11, 2015 in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of California, San Diego School of Medicine
Agilent Technologies 
Life Technologies 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.